Dana-Farber Cancer Institute
T

ASCO® GU 2024 Insights: "OS Results From the KEYNOTE-564 Study - Adjuvant Pembro vs. Placebo for the Treatment of ccRCC"

By Dana-Farber Cancer Institute FEATURING Toni Choueiri
By Dana-Farber Cancer Institute FEATURING Toni Choueiri
52 views
February 20, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

19:47
Janssen Oncology

All Things PSA

Feat. J. Hamilton, M. Fabrizio, M. Taha

Featured Video

21:17
Janssen Oncology

The Man Cave

Feat. J. Hamilton, M. Fabrizio, M. Taha

Related Content

AUTOPLAY
16:05
Insights from 2024 ASCO® GU Annual Meeting

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini
13:37
SIR 2023 Conference Coverage

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

Feat. N. Kothary
15:58
Total Health

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Feat. M. Reimers
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
07:27
Jason Levy

Opus One: Final Results - RFA in Axial Skeleton

19:41
Balazs Halmos

How I Manage Immune Adverse Events in Solid Tumors

07:10
Viktor Grünwald

Updated Results From the CLEAR Trial: Outcomes of the Combination of…

16:19
OncoAlert

Year in Review: RCC Practice Changing and Practice Informing Trials …

Feat. T. Choueiri
09:12
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Cabozantinib, Nivolumab, and Ipilimumab f…

Feat. B. McGregor
15:17
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Systemic Therapy for Recurrent Metastatic RCC: Beyond S…

Feat. T. Zhang
15:44
Matthew Campbell

How to Select Frontline Therapy for Metastatic Clear Cell RCC

09:54
Insights from 2024 ASCO® GU Annual Meeting

The Impact of Immunotherapy-Based Regimens in Primary Renal Tumors

Feat. R. McKay
09:35
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "State-of-the-Art in Adjuvant Treatment of …

Feat. G. de Velasco
29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

23:16
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Optimizing Therapy Selection for Patients…

Feat. B. McGregor
10:27
Robert McBane

2023 ISTH Insights: "The EVE Trial - Extending VTE Secondary Pr…

22:03
Dana-Farber Cancer Institute

RCC Highlights From ASCO® GU 2024

Feat. W. Xu, T. Choueiri
09:03
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "Long-Term Follow-Up Data From the Chec…

Feat. D. McDermott
19:42
International Urology Cancer Summit - IUCS

How to Choose 1L Therapy for mRCC

Feat. M. Pal
15:50
Pavlos Msaouel

First-Line Treatment Options in Advanced RCC: How to Choose